Cancer drugs: getting more for your money – by Karol Sikora
This article was originally published in Scrip
Executive Summary
Cancer treatment is undergoing a revolution, driven by ageing populations, advanced technologies and an increasingly informed society. Health economics considerations and top-up payments are gaining traction in some markets. And personalised healthcare in cancer is a costly yet completely justifiable goal. Without the necessary investment industry should expect more product failures, says Karol Sikora